Hostname: page-component-848d4c4894-2xdlg Total loading time: 0 Render date: 2024-07-04T18:51:14.582Z Has data issue: false hasContentIssue false
  • English
  • Français

Assessing Data Sources for Medicine Price Studies

Part of: Special Collection - Methods

Published online by Cambridge University Press:  29 March 2019

Sabine Vogler Open the ORCID record for Sabine Vogler [Opens in a new window]  and
Peter Schneider
Sabine Vogler*
Affiliation:
WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Pharmacoeconomics Department, Gesundheit Österreich GmbH (GÖG / Austrian Public Health Institute), Vienna, Austria
Peter Schneider
Affiliation:
WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Pharmacoeconomics Department, Gesundheit Österreich GmbH (GÖG / Austrian Public Health Institute), Vienna, Austria
*
Author for correspondence: Sabine Vogler, Email: sabine.vogler@goeg.at
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives

There is no established methodology to assess the feasibility of medicine price data sources. Against this backdrop, a framework to guide the selection of most appropriate price data sources for pharmacoeconomic research has been developed.

Methods

A targeted literature review was carried out. Dimensions discussed in literature as relevant for medicine price comparisons and practical experience of the authors in medicine price studies informed the conceptional work of the framework development. A draft version of the framework was reviewed by peer pricing experts. The feasibility of the framework was tested in case studies.

Results

According to the developed framework (called Re-ADAPT), a medicine price data source should meet the following criteria: reliability and sustainability; accessibility at a cost that users can afford; provision of medicine price information at the date(s) required; information for the defined geographic area, or at least in a representative way; coverage of the pharmaceuticals and at the price type(s) required. Easy handling and provision of additional information were defined as supportive assets of candidate data sources (secondary criteria). The case studies confirmed the feasibility of the Re-ADAPT framework. In some cases, however, it can be difficult to disentangle assessment criteria (particularly geographic area, scope of pharmaceuticals and price types) for separate consideration, given their interlinkage.

Conclusions

While selection of the most appropriate data sources will remain a challenge, the Re-ADAPT framework aims to provide practical guidance and thus contribute to a more careful, balanced, and evidence-based selection of data sources for medicine price studies.

Keywords

Medicine pricesMethodsAssessmentSelection criteriaPrice database
Type
Method
Information
International Journal of Technology Assessment in Health Care , Volume 35 , Issue 2 , 2019 , pp. 106 - 115
Copyright
Copyright © Cambridge University Press 2019 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Drummond, MF, Wilson, DA, Kanavos, P, Ubel, P, Rovira, J (2007) Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care 23, 36–42.Google Scholar
2.Henshall, C, Mardhani-Bayne, L, Fronsdal, KB, Klemp, M (2011) Interactions between health technology assessment, coverage, and regulatory processes: Emerging issues, goals, and opportunities. Int J Technol Assess Health Care 27, 253–260.Google Scholar
3.Henshall, C, Schuller, T (2013) Health technology assessment, value-based decision making, and innovation. Int J Technol Assess Health Care 29, 353–359Google Scholar
4.WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies. (2016) Glossary of pharmaceutical terms. Update 2016. Vienna. https://ppri.goeg.at/sites/ppri.goeg.at/files/inline-files/Glossary_Update2016_final.pdf.Google Scholar
5.Andersson, F (1993) Methodological aspects of international drug price comparisons. Pharmacoeconomics 4, 247–256.Google Scholar
6.Danzon, PM, Kim, JD (1998) International price comparisons for pharmaceuticals. Pharmacoeconomics 14, 115–128.Google Scholar
7.Machado, M, O'Brodovich, R, Krahn, M, Einarson, TR (2011) International drug price comparisons: Quality assessment. Rev Panam Salud Publica 29, 46–51.Google Scholar
8.WHO, HAI (2003) Medicine prices. A new approach to measurement. Working draft for field testing and revision. Geneva: World Health Organization, Health Action International.Google Scholar
9.WHO, HAI (2008) Measuring medicine prices, availability, affordability and price components. 2nd ed. Geneva: World Health Organization, Health Action International.Google Scholar
10.Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the pricing of medicinal products for human use and their inclusion in the scope of national health insurance systems.Google Scholar
11.World Health Organization (2017) Medicine price information sources. http://www.who.int/medicines/areas/access/med_price_info_sources/en/.Google Scholar
12.Hinsch, M, Kaddar, M, Schmitt, S (2014) Enhancing medicine price transparency through price information mechanisms. Global Health 10, 34.Google Scholar
13.Walley, T, Folino-Gallo, P, Barry, M, et al. (2006) The EurMedStat proposals on indicators for price and utilisation. Ital J Public Health 3, 15–21.Google Scholar
14.World Health Organization. Medicine price information sources. http://www.who.int/medicines/areas/access/med_price_info_sources/en/.Google Scholar
15.Panteli, D, Arickx, F, Cleemput, I, et al. (2016) Pharmaceutical regulation in 15 European countries. Review. Health Syst Transit 18, 1–118.Google Scholar
16.Busse, R, Panteli, D, Schaufler, J, Schröder, H (2016) Europäischer Preisvergleich für patentgeschützte Arzneimittel [European Price Comparision for On-Patent Medicines]. Berlin: Springer.Google Scholar
17.Wagner, JL, McCarthy, E (2004) International differences in drug prices. Annu Rev Public Health 25, 475–495.Google Scholar
18.Petrou, P, Talias, MA (2016) Navigating through the maze of pricing and affordability of branded pharmaceuticals in the midst of the financial crisis: A comparative study among five European recession countries, from a Cyprus perspective. J Pharm Policy Pract 9, 1.Google Scholar
19.World Health Organization (2013) WHO guideline on country pharmaceutical pricing policies. Geneva: WHO.Google Scholar
20.Vogler, S, Habl, C, Bogut, M, Voncina, L (2011) Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States. Croat Med J 52, 197.Google Scholar
21.Vogler, S, Zimmermann, N, Habimana, K (2014) Study of the policy mix for the reimbursement of medicinal products. Proposal for a best practice-based approach based on stakeholder assessment. Vienna: Commissioned by the European Commission.Google Scholar
Supplementary material: File

Vogler and Schneider supplementary material

Vogler and Schneider supplementary material 1

Download Vogler and Schneider supplementary material(File)
File 88.1 KB